Review of duloxetine in the management of diabetic peripheral neuropathic pain

(2458) Views  (643) Full article downloads

Authors: Timothy Smith, Robert A Nicholson

Published Date January 2007 Volume 2007:3(6) Pages 833 - 844

DOI: http://dx.doi.org/10.2147/VHRM.S

Timothy Smith¹, Robert A Nicholson²

¹Mercy Health Research Ryan Headache Center, St. Louis, MO, USA; ²Department of Family Medicine, Saint Louis University School of Medicine, St. Louis, MO, USA

Abstract: Duloxetine is a balanced selective serotonin norepinephrine reuptake inhibitor (SNRI) which, in 2004, became the first agent to receive regulatory approval for the treatment of painful diabetic neuropathy in the US. This compound has no other significant receptor or channel activities other than the serotonin and norepinephrine reuptake inhibition mechanisms and works to diminish or control the symptoms of diabetic neuropathy. Duloxetine has no known neuroprotective or other effects which prevent the development of neuropathy in patients with diabetes. The purpose of this review article is to discuss the background of painful diabetic neuropathy, the pharmacology of duloxetine, and its safety and efficacy in clinical trials and long-term observations. The authors will also comment on its use in clinical practice. Results from controlled clinical trials reveal that duloxetine administered at 60 mg qd or 60 mg bid is efficacious in treating diabetic neuropathic pain relative to placebo. Positive treatment outcomes are also seen for other measures of pain and quality of life. A minor but statistically significant increase in blood glucose compared with placebo treated patients has been observed in controlled clinical trials. Otherwise, controlled and open-label clinical studies have demonstrated a high degree of safety and tolerability for the compound. These findings provide support for the proposed role of serotonin and norepinephrine as key mediators of the descending pain inhibition pathways of the brain stem and spinal cord.

Keywords: duloxetine, diabetic neuropathy, selective serotonin norepinephrine reuptake inhibitor (SNRI), central sensitization